Long-acting Oral Formulation of Doxycycline: In vitro-in vivo Correlation Studies

被引:1
作者
Arciniegas, Sara M. [1 ]
Bernad, Maria J. [2 ]
Carlin, S. C. [3 ]
Juarez, I. [4 ]
Vargas, Dinorah [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Vet Med Sch, Physiol & Pharmacol Dept, Univ 3000,Circuito Exterior S-N Delegac, Mexico City 04510, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Chem Fac, Pharmaceut Technol, Univ 3000,Circuito Exterior S-N Delegac, Mexico City 04510, DF, Mexico
[3] Univ Nacl Autonoma Mexico, Dept Anim Nutr, Natl Inst Med Sci & Nutr Salvador Zubiran, Mexico City, DF, Mexico
[4] Univ Nacl Autonoma Mexico, Vet Med Sch, Dept Prevent Med & Publ Hlth, Mexico City, DF, Mexico
关键词
Dissolution; bioavailability; in vitro models; oral drug delivery; polymeric drugs; DISSOLUTION; PHARMACODYNAMICS; PHARMACOKINETICS; PERFORMANCE; RELEASE; SYSTEMS; SAFETY;
D O I
10.36468/pharmaceutical-sciences.551
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to establish and validate an in vitro-in vivo correlation that could predict the bioavailability of 4 oral long-acting formulations of doxycycline hyclate, acrylic acid and polymethacrylate matrices prepared using various proportions of doxycycline:acrylic acid:polymethacrylate for formulation 1 (1:0.25:0.0035), formulation 2 (1:0.5:0.0075), formulation 3 (1:1:0.015) and formulation 4 (1:2:0.0225) and a sample of doxycycline without excipients. In vitro dissolution profiles were obtained in phosphate buffer and hydrochloric acid media, which were fitted to several mathematical models. Plasma concentrations were obtained from 48 healthy dogs to achieve in vivo profiles. Therapeutic concentrations were observed for 60 h for formulation 1 and 4, 48 h for formulation 2 and 3 and 24 h for the sample of doxycycline. None of the pharmacokinetic parameter differed significantly between formulation 1 and 2 or between formulation 3 and 4; however, doxycycline differed significantly in comparison. The in vivo-in vitro correlation coefficient obtained from point-to-point analysis >0.999 for formulation 3 and 4 and >0.9581 for the others. To validate the model, the absorbed fractions for all formulations were estimated to predict plasma concentration profiles. In conclusion, adequate in vitro-in vivo correlation was established for long-acting formulations of doxycycline indicating that in vitro dissolution tests could be used as a surrogate for bioavailability studies.
引用
收藏
页码:608 / 617
页数:10
相关论文
共 30 条
[1]   Non-linear mixed effects models for the evaluation of dissolution profiles [J].
Adams, E ;
Coomans, D ;
Smeyers-Verbeke, J ;
Massart, DL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 240 (1-2) :37-53
[2]   Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines [J].
Agwuh, Kenneth N. ;
MacGowan, Alasdair .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) :256-265
[3]   Comparative pharmacokinetics of a new oral long-acting formulation of doxycycline hyclate: A canine clinical trial [J].
Arciniegas Ruiz, Sara Melisa ;
Gutierrez Olvera, Lilia ;
Bernad Bernad, Maria Josefa ;
Caballero Chacon, Sara del Carmen ;
Vargas Estrada, Dinorah .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 80 :9-15
[4]  
Banker G, 2002, MODERN PHARMACOKINET, P124
[5]   Multimodel inference - understanding AIC and BIC in model selection [J].
Burnham, KP ;
Anderson, DR .
SOCIOLOGICAL METHODS & RESEARCH, 2004, 33 (02) :261-304
[6]   In vitro-in vivo correlation: Importance of dissolution in IVIVC [J].
Cardot, J-M. ;
Beyssac, E. ;
Alric, M. .
DISSOLUTION TECHNOLOGIES, 2007, 14 (01) :15-19
[7]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[8]   Pharmacodynamics of doxycycline [J].
Cunha, BA ;
Domenico, P ;
Cunha, CB .
CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (05) :270-273
[9]  
Emami J, 2006, J PHARM PHARM SCI, V9, P169
[10]  
FDA, 1997, GUID IND EXT REL OR